Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), believes that broadening communication and education is COA’s main goal in 2018.
Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), believes that broadening communication and education is COA’s main goal in 2018.
Transcript
What do you see COA’s role being in the coming year in regard to OCM implementation?
Broaden the communication, broaden the education. Someone gave me a book recently and it’s titled The Speed of Trust and I think it’s very practical, very interesting. It talks about how we change in our society, we’re just not as trustful as we need to be.
I think we need to build the trust component in everything we do. Meaning someone called us one time an honest broker. Give it to COA, an honest broker. That’s a very high compliment, but it also comes with a great deal of responsibility. We need to continue that process. Speak openly, speak honestly, do a little education, and bring people home. I've been with COA for 7 years, with a major cancer care team for 13 years, and doing cancer care for 20 years, and though we’ve been saying the same thing for 5 or 6 years, recently someone who I’ve known for a long time says, "In the sales community you have to say it 6 times before it resonates." So I’m thinking, "okay we need to say it 6 times real fast," but we have to take our time, rearrange our words, say them differently so that it makes sense and it sits with people. And they have that V8 moment like, "wow I need to," and then they’ll implement it. There will be a lot of fault starts but you have to encourage them so they can continue to move forward.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More